|
[1]
|
Xiong, X. and Li, X. (2023) Type 2 Diabetes Originated from Non-Alcoholic Fatty Liver Disease. Life Metabolism, 2, load007. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Khneizer, G., Rizvi, S. and Gawrieh, S. (2020) Non-Alcoholic Fatty Liver Disease and Diabetes Mellitus. In: Advances in Experimental Medicine and Biology, Springer International Publishing, 417-440. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Pinto, R.V., Carvalho, S., Antunes, F., Pires, J. and Pinto, M.L. (2021) Emerging Nitric Oxide and Hydrogen Sulfide Releasing Carriers for Skin Wound Healing Therapy. ChemMedChem, 17, e202100429. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ni, W.J., Li, J. and Nan, Y.M. (2024) Interpretation of the 2024 American Diabetes Association Guidelines for the Comprehensive Management of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Mellitus. Chinese Journal of Hepatology, 32, 504-507.
|
|
[5]
|
Bica, C., Sandu, C., Suceveanu, A., Sarbu, E., Stoica, R., Gherghiceanu, F., et al. (2020) Non-Alcoholic Fatty Liver Disease: A Major Challenge in Type 2 Diabetes Mellitus (Review). Experimental and Therapeutic Medicine, 20, 2387-2391. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Elkattawy, H.A., Elsherbini, D.M., Ebrahim, H.A., Abdullah, D.M., Al-Zahaby, S.A., Noser, Y. and Hassan, A.E. (2022) Rho-Kinase Inhibition Ameliorates Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Rats. Physiological Research, 71, 615-630. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Zhou, Q., Wang, Y., Wang, J., Liu, Y., Qi, D., Yao, W., et al. (2021) Prevalence and Risk Factor Analysis for the Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Medicine, 100, e24940. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Xie, Y., Kong, W., Wang, X. and Wu, Z. (2022) Association of Glycated Hemoglobin with Non-Alcoholic Fatty Liver Disease Patients and the Severity of Liver Steatosis and Fibrosis Measured by Transient Elastography in Adults without Diabetes. BMC Endocrine Disorders, 22, Article No. 220. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Targher, G., Corey, K.E., Byrne, C.D. and Roden, M. (2021) The Complex Link between NAFLD and Type 2 Diabetes Mellitus—Mechanisms and Treatments. Nature Reviews Gastroenterology & Hepatology, 18, 599-612. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Muthiah, M., Ng, C.H., Chan, K.E., Fu, C.E., Lim, W.H., Tan, D.J.H., et al. (2023) Type 2 Diabetes Mellitus in Metabolic-Associated Fatty Liver Disease Vs. Type 2 Diabetes Mellitus Non-Alcoholic Fatty Liver Disease: A Longitudinal Cohort Analysis. Annals of Hepatology, 28, Article ID: 100762. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zhang, Y., Wang, L., Zheng, X., Wang, H. and Wang, G. (2023) Risk Factors for Macro Vascular Disease in Type 2 Diabetes Mellitus Patients with Non-Alcoholic Fatty Liver Disease. Pakistan Journal of Pharmaceutical Sciences, 36, 1297-1303.
|
|
[12]
|
Chen, L. and Jiang, L. (2022) Clinico-Pathological Features and Related Risk Factors of Type-2 Diabetes Mellitus Complicated with Nonalcoholic Fatty Liver. Pakistan Journal of Medical Sciences, 38, 1771-1775. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kanwal, S., Ghaffar, T., Aamir, A.H. and Usman, K. (2021) Frequency of Non-Alcoholic Fatty Liver Disease in Patients with Type-2 Diabetes Mellitus and Its Associated Risk Factors. Pakistan Journal of Medical Sciences, 37, 1335-1341. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., et al. (2020) Transcriptomic Profiling across the Nonalcoholic Fatty Liver Disease Spectrum Reveals Gene Signatures for Steatohepatitis and Fibrosis. Science Translational Medicine, 12, eaba4448. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kim, K., Hong, S., Han, K. and Park, C. (2024) Association of Non-Alcoholic Fatty Liver Disease with Cardiovascular Disease and All Cause Death in Patients with Type 2 Diabetes Mellitus: Nationwide Population Based Study. BMJ, 384, e076388. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., et al. (2023) Comparative Effectiveness of Multiple Different Treatment Regimens for Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus: A Systematic Review and Bayesian Network Meta-Analysis of Randomised Controlled Trials. BMC Medicine, 21, Article No. 447. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Caussy, C., Aubin, A. and Loomba, R. (2021) The Relationship between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports, 21, Article No. 15. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Ferguson, D. and Finck, B.N. (2021) Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 17, 484-495. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Mansour, A., Mohajeri-Tehrani, M.R., Samadi, M., Qorbani, M., Merat, S., Adibi, H., et al. (2021) Effects of Supplementation with Main Coffee Components Including Caffeine And/or Chlorogenic Acid on Hepatic, Metabolic, and Inflammatory Indices in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Nutrition Journal, 20, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Duan, W., Shi, R., Yang, F., Zhou, Z., Wang, L., Huang, Z., et al. (2023) FSTL3 Partially Mediates the Association of Increased Nonalcoholic Fatty Liver Disease Fibrosis Risk with Acute Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Diabetology, 22, Article No. 297. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Khaliq, A., Badshah, H., Shah, Y., Rehman, I.U., Khan, K.U., Ming, L.C., et al. (2024) The Effect of Ertugliflozin in Patients with Nonalcoholic Fatty Liver Disease Associated with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Medicine, 103, e40356. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Milić, S., Lulić, D. and Štimac, D. (2014) Non-alcoholic Fatty Liver Disease and Obesity: Biochemical, Metabolic and Clinical Presentations. World Journal of Gastroenterology, 20, 9330-9337. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Shibata, C., Nakano, T., Yasumoto, A., Mitamura, A., Sawada, K., Ogawa, H., et al. (2022) Comparison of CEA and CA19-9 as a Predictive Factor for Recurrence after Curative Gastrectomy in Gastric Cancer. BMC Surgery, 22, Article 213. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
汪思亮, 田文君, 陆玮婷, 等. 非酒精性脂肪肝患者合并高血压的相关危险因素分析[J]. 现代医学, 2022, 50(7): 806-810.
|
|
[25]
|
刘春影, 许青, 王飞, 等. 二维剪切波弹性成像对2型糖尿病合并非酒精性脂肪肝病患者肝纤维化的诊断价值[J]. 医疗卫生装备, 2024, 45(9): 73-77.
|
|
[26]
|
Liu, J., Fu, Q., Su, R., Liu, R., Wu, S., Li, K., et al. (2024) Association between Nontraditional Lipid Parameters and the Risk of Type 2 Diabetes and Prediabetes in Patients with Nonalcoholic Fatty Liver Disease: From the National Health and Nutrition Examination Survey 2017-2020. Frontiers in Endocrinology, 15, Article ID: 1460280. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Cao, L., An, Y., Liu, H., Jiang, J., Liu, W., Zhou, Y., et al. (2024) Global Epidemiology of Type 2 Diabetes in Patients with NAFLD or MAFLD: A Systematic Review and Meta-Analysis. BMC Medicine, 22, Article No. 101. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Shi, M., Zhang, H., Wang, W., Zhang, X., Liu, J., Wang, Q., et al. (2023) Effect of Dapagliflozin on Liver and Pancreatic Fat in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease. Journal of Diabetes and its Complications, 37, Article ID: 108610. [Google Scholar] [CrossRef] [PubMed]
|